BOBerrin Oztas

Berrin Oztas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Berrin Oztas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endothelial Leakage–Erythrocyte Stress Index for the prediction of pre-eclampsia in the first trimester

    by Funda Demirel, Berrin Oztas

    Pre-eclampsia is a major cause of maternal and perinatal morbidity, and there remains a need for reliable and easily accessible biomarkers for early prediction. The Endothelial Leakage–Erythrocyte Stress (ELES) index is a novel composite biomarker derived from routine first-trimester red cell distribution width (RDW), aspartate aminotransferase (AST), and serum albumin, reflecting endothelial leakage and erythrocyte stress. This retrospective case-control study evaluated the predictive value of the ELES index for pre-eclampsia in singleton pregnancies undergoing routine laboratory assessment at 11–13 + 6 weeks who delivered at the same hospital. First-trimester ELES index values were significantly higher in women who later developed pre-eclampsia than in controls (6.36 ± 2.59 vs 4.75 ± 1.38, P < .001), with an AUC of 0.75 (95% CI: 0.65–0.85); at a cutoff of ≥5, sensitivity and specificity were 76.3% and 65.0%, respectively. After adjustment for maternal age and obstetric characteristics, ELES ≥ 5 remained independently associated with pre-eclampsia (OR 5.971, 95% CI: 2.427–14.688, P = .001); higher AST and lower albumin were also independently associated. Albumin alone yielded the highest AUC (0.775, 95% CI: 0.689–0.847), and the ELES index was not statistically superior to albumin alone (DeLong P = .698). Because first-trimester albumin is not part of routine national antenatal screening, only women in whom this measurement had already been requested could be analyzed, and BMI, aspirin prophylaxis, gestational age at diagnosis, and disease severity were not retrievable. These findings should therefore be regarded as preliminary and hypothesis-generating, requiring prospective validation in a broader obstetric population before clinical use.

  • Comparative evaluation of diagnostic and analytical performance of DIRUI FUS-200 and MUS-3600 fully automated urine analyzers

    by Berrin Oztas, Fatih Hunc, Berna Yildirim Şik, Hale Kir

    The aim was to assess and compare the analytical performance of the FUS-200 and its new upgrade, the MUS-3600 urine autoanalyzers, and to compare performance with manual microscopy. First morning, void urine samples were randomly collected, and suitable samples were analyzed on both autoanalyzers. In addition, concurrent manual microscopic examinations were performed for all suitable urine samples. Carry-over, linearity and imprecision analysis were performed to assess analytical and diagnostic performance of both urine autoanalyzers according to Clinical and Laboratory Standards Institute (CLSI) EP15-A2, and the study was conducted in accordance with CLSI GP16-A3 Urinalysis; Approved Guideline. A total of 518 samples were collected, and of these, 494 (95.4%) were suitable for analysis and were included in the study. Sensitivity and positive likelihood ratio (LR+) values for WBC and squamous epithelium (SqEC) counts for both autoanalyzers were >90% and >10%, respectively. Specificity and LR+ values obtained from MUS-3600 were better compared to the FUS-200 (respectively 92.8 vs. 84.7; 5.5 vs. 10.1). One group agreement between the MUS-3600 and manual microscopy was >90%. Both analyzers displayed comparable performance for RBC and WBC counts, which were moderately correlated with each other. These results show the diagnostic performance of the MUS-3600 and FUS-200 was satisfactory for urine sediment analysis and was compatible with manual microscopy findings. However, random urine samples are sub-optimal for evaluating diagnostic performance, particularly for bacterial, cast, crystal and yeast analysis. Thus, we recommend using more appropriate urine samples for this comparison, such as from patients with suspected urinary tract infections.


  • EFFECTS OF USING CLINICAL DECISION SUPPORT TOOLS ON VITAMIN D COST EFFECTIVENESS

    by Zeynep Mi̇nE Yalçinkaya Kara, David Ojalvo, Berri̇n Öztaş, Erdi̇nÇ Seri̇n

    Amaç: D vitamini testleri tıbbi uygulamada tüm dünyada yaygın olarak talep edilmektedir. Birçok laboratuvar, sistem üzerindeki gereksiz talep yükünü ve dolayısıyla maliyet yükünü azaltmak için klinik karar destek sistemlerinin kullanımına yönelmektedir. Bu çalışmada D vitamini test isteği öncesi ve sonrasında uygulanan klinik karar destek sistemlerinin maliyete ve test isteğindeki değişime etkisi incelenmiştir. Gereç ve Yöntem: Klinik karar destek sistemlerinin hastane yazılım sistemine girmesinden önceki (8/12/2018-8/03/2019) ve sonrası (9/03/2019-9/06/2019) 90 gün boyunca test isteklerini analiz ettik. Bu sistem, hastanın son 90 gün içinde D vitamini testi yaptırıp yaptırmadığını belirten bir ekran uyarısı oluşturur. Yoğun bakım ve yatan hastalar hariç bazı kliniklerden gelen test isteklerini tamamen engellerken, diğerlerinde tanıya bağlı test istemine izin vermektedir. Test istemlerini analiz etmek için Microsoft Excel’in Pivot Tablo aracı kullanıldı. Klinik karar destek sistemlerinin tanıtılmasından önceki ve sonraki test maliyetleri karşılaştırıldı. Bulgular: İlk dönemde 31,066 25(OH) D vitamini talebi oldu. İkinci dönemde aynı analit için 18,830 talep geldi. Dolayısıyla test isteminde yaklaşık %39’luk (12,236 test) bir azalma gerçekleşti (p<0.0001). Bu da, üç ayda 37.350 ABD Doları veya tahmini yıllık yaklaşık 150,000 ABD Doları tasarruf olarak hesaplanmıştır. Sonuç: Hastanenin yazılım sistemine klinik karar destek sistemlerinin eklenmesi, 25(OH) D vitamini testi talebinde ve maliyette önemli bir azalma ile sonuçlanmıştır. Laboratuvarlarda yeni klinik yazılım sistemlerinin geliştirilmesi ve kullanılması hem kaynak hem de insan işgücü verimliliği açısından önemlidir.

  • Open Access

    Do Alarmins Have a Role in Multiple Myeloma?

    by Ayfer Gedük, Merve Gökçen Polat, Esra Terzi Demirsoy, Berrin Öztaş, Baldan Huri Eryılmaz, Emel Merve Yenihayat, Hayrunnisa Albayrak, Haşim Atakan Erol, Özgür Mehtap, Pınar Tarkun, et al.

    Objective: Calprotectin (CLP), S100A6, and high mobility group nucleosome-binding protein 1 (HMGN1), known as alarmins, are involved in the pathogenesis of many tumors. In this study, we aimed to investigate the relationships of serum CLP, S100A6, and HMGN1 levels with the clinical and laboratory findings of patients with multiple myeloma (MM) and their roles in the pathogenesis of MM. Materials and methods: We measured the serum CLP, S100A6, and HMGN1 levels of 55 newly diagnosed patients and 32 healthy controls using the sandwich enzyme-linked immunosorbent assay method. The medical records of the patients were also reviewed. Results: Serum CLP, S100A6, and HMGN1 levels were significantly decreased in MM patients compared to the control group (p=0.012, p=0.001, and p=0.030, respectively). Receiver operating characteristic analysis was used to determine diagnostic cut-off values for serum CLP, S100A6, and HMGN1 of <98 ng/mL (area under the curve [AUC]: 0.663, 95% confidence interval [CI]: 0.554-0.761, p=0.009), <1174.5 pg/mL (AUC: 0.706, 95% CI: 0.598-0.799, p=0.001), and <440.18 pg/mL (AUC: 0.640, 95% CI: 0.530-0.740, p=0.03), respectively. CLP levels were found to be statistically significantly higher in patients with light chain MM (91.58 +/- 22.57 ng/mL) compared to heavy chain MM (79.42 +/- 15.83 ng/mL) (p=0.03). A negative correlation was observed between CLP and M protein, immunoglobulin G, globulin, and beta-2 microglobulin (correlation coefficients: -0.361, -0.370, -0.279, -0.300, respectively; p=0.024, p=0.06, p=0.04, p=0.0033). Conclusion: In this study, we found that serum CLP, S100A6, and HMGN1 levels were statistically lower in patients with newly diagnosed MM compared to the control group. These results suggest that CLP may bind to the paraprotein produced by heavy chain MM in the blood, causing its blood levels to be low. Additionally, low levels of HMGN1, which is involved in DNA repair, suggest that HMGN1 may contribute to the complex genetic abnormalities found in cases of MM.


  • Open Access

    Correction to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma

    by Ayfer Geduk, Berrin Oztas, Baldan Huri Eryılmaz, Esra Terzi Demirsoy, Meral U. Menguc, Serkan Unal, Sinan Mersin, Merve Gokcen Polat, Kemal Aygun, Emel Merve Yenihayat, et al.

    [This corrects the article DOI: 10.1007/s12288-022-01574-6.].

  • Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma

    by Ayfer Geduk¹, Berrin Oztas, Baldan Huri Eryılmaz, Esra Terzi Demirsoy, Meral U. Menguc, Serkan Unal, Sinan Mersin, Merve Gokcen Polat, Kemal Aygun, Emel Merve Yenihayat, et al.

    Purpose The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of serum advanced glycation end products (AGEs), soluble RAGE (sRAGE) and high mobility group box 1 (HMGB1), in multiple myeloma (MM). Methods AGEs, sRAGE and HMGB1 concentrations of 54 newly diagnosed MM patients and 30 healthy volunteers were measured by ELISA. The estimations were done only once at diagnosis. The medical records of the patients were evaluated. Results There was no significant difference between the AGEs and sRAGE levels between the patient and control groups (p = 0.273, p = 0.313). In ROC analysis, a HMGB1 cutoff value of > 9170 pg/ml accurately discriminated MM patients (AUC = 0.672, 95% CI 0.561–0.77, p = 0.0034). AGEs level was found to be significantly higher in early-stage disease and HMGB1 in advanced disease (p = 0.022, p = 0.026). High HMGB1 levels were detected in patients whose with better first-line treatment response (p = 0.019). At 36 months, 54% of patients with low AGE were alive, compared to 79% of patients with high AGE (p = 0.055). Patients with high HMGB1 levels tended to have a longer PFS (median 43 mo [95% CI; 20.68–65.31] ) compared to patients with low HMGB1 levels (median 25 mo [95% CI; 12.39–37.6], p = 0.054). Conclusion In this study, a significant elevation of serum HMGB1 level was found in MM patients. In addition, the positive effects of RAGE ligands on treatment response and prognosis were determined.